ATHA Athira Pharma Inc
Price (delayed)
$0.4341
Market cap
$16.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.85
Enterprise value
-$59.13M
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira aims to provide rapid cognitive
Highlights
The company's debt fell by 21% YoY and by 7% QoQ
The EPS is up by 10% YoY and by 4% QoQ
ATHA's equity has plunged by 63% YoY and by 31% from the previous quarter
ATHA's quick ratio has plunged by 54% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of ATHA
Market
Valuations
Earnings
Shares outstanding
38.67M
Market cap
$16.79M
Enterprise value
-$59.13M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$114.35M
Net income
-$109.22M
EBIT
-$109.22M
EBITDA
-$108.02M
Free cash flow
-$97.48M
Per share
Balance sheet
Liquidity
EPS
-$2.85
EPS diluted
-$2.85
Free cash flow per share
-$2.53
Book value per share
$1.5
Revenue per share
$0
TBVPS
$2.24
Total assets
$86.25M
Total liabilities
$28.66M
Debt
$1.31M
Equity
$57.58M
Working capital
$54.25M
Debt to equity
0.02
Current ratio
2.95
Quick ratio
2.78
Net debt/EBITDA
0.7
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-88.9%
Return on equity
-115.6%
Return on invested capital
-734.9%
Return on capital employed
-186.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATHA stock price
How has the Athira Pharma stock price performed over time
Intraday
-3.21%
1 week
-7.24%
1 month
-19.51%
1 year
-88.27%
YTD
-26.01%
QTD
-26.01%
Financial performance
How have Athira Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$114.35M
Net income
-$109.22M
Gross margin
N/A
Net margin
N/A
ATHA's operating income is up by 12% YoY and by 4.5% from the previous quarter
ATHA's net income is up by 9% year-on-year and by 3.7% since the previous quarter
Growth
What is Athira Pharma's growth rate over time
Valuation
What is Athira Pharma stock price valuation
P/E
N/A
P/B
0.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 10% YoY and by 4% QoQ
ATHA's P/B is 74% below its 5-year quarterly average of 1.1 and 64% below its last 4 quarters average of 0.8
ATHA's equity has plunged by 63% YoY and by 31% from the previous quarter
Efficiency
How efficient is Athira Pharma business performance
The ROIC has plunged by 100% from the previous quarter
ATHA's return on equity has dropped by 89% year-on-year and by 21% since the previous quarter
Athira Pharma's ROA has plunged by 63% YoY and by 15% from the previous quarter
Dividends
What is ATHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATHA.
Financial health
How did Athira Pharma financials performed over time
ATHA's quick ratio has plunged by 54% YoY and by 25% from the previous quarter
Athira Pharma's current ratio has plunged by 53% YoY and by 26% from the previous quarter
The company's debt is 98% lower than its equity
The company's debt to equity has surged by 100% YoY
ATHA's equity has plunged by 63% YoY and by 31% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.